The Synthesis, Structural Modification and Mode of Anticancer Action of Evodiamine: A Review

被引:8
作者
Fan, Meixia [1 ]
Yao, Lei [1 ]
机构
[1] Yantai Univ, Sch Pharm, 30 Qingquan Rd, Yantai 264005, Shandong, Peoples R China
关键词
Antitumor; drug design; evodiamine; mode of action; patent; synthesis; structural modification; TOPOISOMERASE-I; HIGHLY POTENT; KAPPA-B; DERIVATIVES; CANCER; PROLIFERATION; APOPTOSIS; RUTAECARPINE; CELLS; DISCOVERY;
D O I
10.2174/1574892817666211221165739
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Finding novel antitumor reagents from naturally occurring alkaloids is a widely accepted strategy. Evodiamine, a tryptamine indole alkaloid isolated from Evodia rutaecarpa, has a wide range of biological activities, such as anti-tumor, anti-inflammation, and anti-bacteria. Hence, research on the structural modification of evodiamine will facilitate the discovery of new antitumor drugs. Objective: The recent advances in the synthesis of evodiamine, and studies on the drug design, biological activities, and structure-activity-relationships of its derivatives, published in patents and primary literature, are reviewed in this paper. Methods: The literature, including patents and follow-up research papers from 2015 to 2020, related to evodiamine is searched in the Scifinder, PubMed, Espacenet, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The keywords are evodiamine, synthesis, modification, anticancer, mechanism. Results: The synthesis of evodiamine is summarized. Then, structural modifications of evodiamine are described, and the possible modes of action are discussed. Conclusion: Evodiamine has a 6/5/6/6/6 ring system, and the structural modifications are focused on rings A, D, E, C-5, N-13, and N-14. Some compounds show promising anticancer potentials and warrant further study.
引用
收藏
页码:284 / 296
页数:13
相关论文
共 115 条
[51]  
Li Xiaoping, OPER RES PERSPECT, V2, P13, DOI [10.1016/j.orp.2014.12.001, DOI 10.1016/J.TETLET.2014.04.120, DOI 10.1016/J.ORP.2014.12.001]
[52]   Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer [J].
Li, Xinglin ;
Wu, Shanchao ;
Dong, Guoqiang ;
Chen, Shuqiang ;
Ma, Zonglin ;
Liu, Dan ;
Sheng, Chunquan .
ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (04) :439-444
[53]   Optical evodiamine derivatives: Asymmetric synthesis and antitumor activity [J].
Li, Zhen-Gang ;
Dong, Guo-Qiang ;
Wang, Sheng-Zheng ;
Miao, Zhen-Yuan ;
Yao, Jian-Zhong ;
Zhang, Wan-Nian ;
Sheng, Chun-Quan .
CHINESE CHEMICAL LETTERS, 2015, 26 (03) :267-271
[54]   A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade [J].
Liang, Xiaoxia ;
Wu, Qiang ;
Luan, Shangxian ;
Yin, Zhongqiong ;
He, Changliang ;
Yin, Lizi ;
Zou, Yuanfeng ;
Yuan, Zhixiang ;
Li, Lixia ;
Song, Xu ;
He, Min ;
Lv, Cheng ;
Zhang, Wei .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 171 :129-168
[55]   Evodiamine via targeting nNOS and AMPA receptor GluA1 inhibits nitroglycerin-induced migraine-like response [J].
Lin, Jiacheng ;
Zhang, Xu ;
Li, Chaotong ;
Zhang, Yingyan ;
Lu, Hanzhi ;
Chen, Jiwei ;
Li, Zeyu ;
Yang, Xuejun ;
Wu, Zhongping .
JOURNAL OF ETHNOPHARMACOLOGY, 2020, 254
[56]   Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells [J].
Lin, Li ;
Ren, Li ;
Wen, Liujing ;
Wang, Yu ;
Qi, Jin .
MOLECULAR MEDICINE REPORTS, 2016, 14 (03) :2832-2838
[57]   Evodiamine induces reactive oxygen species-dependent apoptosis and necroptosis in human melanoma A-375 cells [J].
Liu, Ning ;
Li, Yongxi ;
Chen, Guanzhi ;
Ge, Keli .
ONCOLOGY LETTERS, 2020, 20 (04)
[58]  
Luo H, 2017, Patent, Patent No. [CN107141288, 107141288]
[59]  
Luo H, 2018, Patent, Patent No. [WO2018188446, 2018188446]
[60]   Beneficial effects of evodiamine on P2X4-mediated inflammatory injury of human umbilical vein endothelial cells due to high glucose [J].
Lv, Qiulan ;
Xue, Yun ;
Li, Guodong ;
Zou, Lifang ;
Zhang, Xi ;
Ying, Mofeng ;
Wang, Shouyu ;
Guo, Lili ;
Gao, Yun ;
Li, Guilin ;
Xu, Hong ;
Liu, Shuangmei ;
Xie, Jinyan ;
Liang, Shangdong .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 28 (02) :1044-1049